Task variability/correlations decrease independently of mean task activity removal step in fMRI data. by Takuya Ito (57473)

Mean±SD of BTT and threshold in control, tinnitus and PBMT groups. by Katayoon Montazeri (18389243)

Subjects:

Immunohistochemical analysis of p-Akt expression in various experimental groups showing negative expression in control group, marked increased expression along the extended fibrous bands (upper insert) in TAA group, significant dose-related decreased expression following the decreased fibroplasia in RBO treated groups, and limited expression in SIL treated group. by Rehab F. Abdel-Rahman (11886404)

Between groups comparison of BTT and threshold in control, tinnitus and PBMT groups. by Katayoon Montazeri (18389243)

Subjects:

Between-groups comparison of GIN and PPI values in control, tinnitus and PBMT groups. by Katayoon Montazeri (18389243)

Subjects:

Laser irradiation in the PBMT group. by Katayoon Montazeri (18389243)

Subjects:

Intention to treat (ITT) means (standard deviations) for outcome and process measures for all participants in the ACT (n = 52) and waitlist control (n = 46) groups. by Arianna Prudenzi (12436789)

Pre and post-treatment mean EPG values on days 0, 7, 14, 21, and 28. by Sohail Afzal (10850709)

Subjects:

Food intake in groups A, B and C. by Sohail Afzal (10850709)

Subjects:

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

“…Bars with different letters differ significantly at P < 0.01 (A), P < 0.05 (B, D), P < 0.0001 (C, E), P < 0.001 (F).…”

Doublecortin (DCX) expression in 3 brain regions (coronal sections) in the control (Cont), Tinnitus (TIN) and PBMT (PBMT) groups. by Katayoon Montazeri (18389243)

Subjects:

Bar graphs of DCX expression evaluated in three brain regions in the control (Cont), Tinnitus (TIN) and PBMT (PBMT) groups. by Katayoon Montazeri (18389243)

Subjects:

Capsaicin, pyridoxine, vincristine sulfate and ionomycin significantly decreased axon length ratio but only pyridoxine had no impact on neurotoxicity. by Fei San Lee (17282886)

“…(<b>C</b>) Pyr at 500 μM significantly decreased axon length ratio over time and was significantly lower than PBS control by day 3. …”

Mean hemoglobin levels of Roxadustat and ESAs groups over time. by Jie Liu (15128)

Subjects:

Immunohistochemical analysis of PDGF-BB expression in various experimental groups; showing negative expression in control group, significant increased along the fibrous septa and along the sinusoidal areas (upper insert) in TAA administrated group, significant dose related decreased expression in RBO which showing scattered expression in the sinusoidal areas, and mild expression along the incomplete septa as well as in sinusoidal areas in silymarin treated group. by Rehab F. Abdel-Rahman (11886404)

Demographic characteristics of study group. by Daniel Lilje (13104379)

Subjects:

Comprehensive overview of results in the study group. by Daniel Lilje (13104379)

Subjects:

Flow-chart of study group selection. by Daniel Lilje (13104379)

Subjects:

Beta diversity in the control and ampicillin-treated groups. by Seogwon Lee (11747633)

Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup. by Jie Liu (15128)

Subjects: